Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices

The development of biotechnology-based active pharmaceutical ingredients, such as GLP-1 analogs, brought changes in type 2 diabetes treatment options. For better therapeutic efficiency, these active pharmaceutical ingredients require appropriate administration, without the development of adverse eff...

ver descrição completa

Detalhes bibliográficos
Autor principal: Pinho, A (author)
Outros Autores: Fortuna, A (author), Falcão, A (author), Santos, AC (author), Seiça, R (author), Estevens, C (author), Veiga, F (author), Ribeiro, A (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
ELISA
Exenatide
HPLC
Therapeutic drug monitoring
Type 2 diabetes
Texto completo:https://hdl.handle.net/10216/136312
País:Portugal
Oai:oai:repositorio-aberto.up.pt:10216/136312

Texto Completo

https://hdl.handle.net/10216/136312

Registos relacionados